Incannex reports Clarion Clinics open for psychedelic-assisted treatments

Incannex Healthcare announced that Clarion Clinic’s co-Founder and Head of Psychiatry, Professor Suresh Sundram, has received Authorised Prescriber approval from the Therapeutic Goods Administration to prescribe MDMA in the treatment of Post-traumatic Stress Disorder and psilocybin for Treatment-resistant Depression at its first built-for-purpose clinic based in Melbourne, Australia, a city of approximately 5.2M people. The Australian TGA Authorised Prescriber Scheme is designed to provide access to certain drugs that are not on the Australian Register of Therapeutic Goods by specially authorising experienced medical practitioners to prescribe them for certain indications. On July 1, 2023, following promising clinical trial results, the TGA down-scheduled MDMA and psilocybin for use in the treatment of PTSD and TRD respectively. This change in drug classification, from Schedule 9 to Schedule 8 is the first down-scheduling of any psychedelic drug globally, permitting the use of these drugs in clinical service delivery through the Authorised Prescriber Scheme. Clarion Clinics is a collaboration between Australia’s leading psychedelic-assisted therapy professionals and scientists, and Incannex. Clarion Clinics, Abbottsford, will be the first dedicated psychedelic-assisted therapy clinic in Australia. Located on the Yarra riverfront in Abbottsford, Melbourne, the clinic has been positioned, designed, and fitted out specifically to facilitate an optimal environment for psychedelic-assisted therapy.